Immune Regulation News Volume 13.19 | May 28 2021

    By
    Justin.choi
    -
    0
    96







    2021-05-28 | IRN 13.19


    Immune Regulation News by STEMCELL Technologies
    Vol. 13.19 – 28 May, 2021
    TOP STORY

    Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy

    Investigators exploited a bilateral surgery model to distinguish responders from non-responders shortly following treatment and identified acute IFN-γ-driven transcriptional remodeling in responder mice, which was also associated with patient benefit to immune checkpoint blockade.
    [Cancer Discovery]

    AbstractPress Release
    NeuroImmune Interactions in Health and Disease
    PUBLICATIONSRanked by the impact factor of the journal

    Dysbiosis Exacerbates Colitis by Promoting Ubiquitination and Accumulation of the Innate Immune Adaptor STING in Myeloid Cells

    Mice bearing an allele rendering STING constitutively active exhibited spontaneous colitis and dysbiosis, as well as progressive chronic intestinal inflammation and fibrosis.
    [Immunity]

    AbstractGraphical Abstract

    Dynamic Regulation of B Cell Complement Signaling Is Integral to Germinal Center Responses

    Scientists found that, as part of a physiologic program, germinal centers B cells repressed expression of decay-accelerating factor and other complement C3 convertase regulators via BCL6, but increased the expression of C5b-9 inhibitor CD59.
    [Nature Immunology]

    Abstract

    Depleting Plasmacytoid Dendritic Cells Reduces Local Type I Interferon Responses and Disease Activity in Patients with Cutaneous Lupus

    To evaluate the potential benefit of depleting plasmacytoid dendritic cells (pDCs) in autoimmunity, a monoclonal antibody targeting the pDC-specific marker immunoglobulin-like transcript 7 was generated.
    [Science Translational Medicine]

    Abstract

    CRISPR/Cas9 Mediated Deletion of the Adenosine A2A Receptor Enhances CAR T Cell Efficacy

    Using both murine and human chimeric antigen receptor T cells, investigators showed that targeting adenosine A2A receptor with a clinically relevant CRISPR/Cas9 strategy significantly enhances their in vivo efficacy,
    [Nature Communications]

    Full ArticlePress Release

    Intratumoral SIRPα-Deficient Macrophages Activate Tumor Antigen-Specific Cytotoxic T Cells under Radiotherapy

    The authors reported that depleting SIRPα on intratumoral macrophages augmented efficacy of radiotherapy to eliminate otherwise large, treatment-resistant colorectal and pancreatic tumors, inducing complete abscopal remission and long-lasting humoral and cellular immunity that prevent recurrence.
    [Nature Communications]

    Full Article

    Chronic T Cell Proliferation in Brains after Stroke Could Interfere with the Efficacy of Immunotherapies

    Researchers identified a potential mechanistic reason for the phenomenon by detecting chronic T cell accumulation—evading the systemic therapy—in the post-ischemic brain.
    [Journal of Experimental Medicine]

    Abstract

    Intravital Imaging Identifies the VEGF-TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion

    Investigators showed that vascular endothelial growth factor VEGF-dependent release of thromboxane A2 (TXA2) triggers Ca2+ transients in tumor cells, culminating in prostaglandin E2 (PGE2) secretion and subsequent immune evasion in the early stages of tumorigenesis.
    [Cancer Research]

    Abstract

    Translational Shutdown and Evasion of the Innate Immune Response by SARS-CoV-2 NSP14 Protein

    Scientists showed that the translation inhibition activity of NSP14 was conserved in human coronaviruses. NSP14 was required for virus replication through contribution of its exoribonuclease and N7-methyltransferase activities.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Full Article
    Breakthroughs take time. Isolating the right cells shouldn't. Learn more.
    REVIEWS

    The Two Facets of gp130 Signaling in Liver Tumorigenesis

    The authors summarize current knowledge on how gp130 signaling and STAT3 in tumor cells and cells of the tumor micro-environment drives hepatic tumorigenesis.
    [Seminars in Immunopathology]

    Full Article
    INDUSTRY AND POLICY NEWS

    Concert Pharmaceuticals Initiates THRIVE-AA2 Phase III Clinical Trial Evaluating CTP-543 for Alopecia Areata

    Concert Pharmaceuticals, Inc. announced it has initiated THRIVE-AA2, the second planned Phase III clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata.
    [Concert Pharmaceuticals, Inc.]

    Press Release

    US Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (Ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

    Bristol Myers Squibb announced that the FDA approved Zeposia® 0.92 mg for the treatment of adults with moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease.
    [Bristol Myers Squibb (BusinessWire, Inc)]

    Press Release
    FEATURED EVENT

    ISSCR 2021 Annual Meeting

    June 21 – 26, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Senior Associate Scientist – Fibrosis Biology

    Gilead Sciences, Inc. – Foster City, California, United States

    Director – The Roslin Institute

    The University of Edinburgh – Edinburgh, Scotland, United Kingdom

    Postdoctoral Fellow – Lung Cancer Development and Progression

    University of Virginia – Charlottesville, Virginia, United States

    Postdoctoral Researcher – Host-Microbiome Interactions

    Kings’s College London – London, England, United Kingdom

    Postdoctoral Position – Intestinal Epithelial Barrier in Autoimmune Diseases

    BioMed X Institute – Heidelberg, Germany

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Immune Regulation News Twitter